Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Mar 1;143(3):393-402.
doi: 10.1097/AOG.0000000000005508. Epub 2024 Jan 16.

Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis

Krishna Nikhila Bonga  1 , Archana Mishra, Rituparna Maiti, Biswa Mohan Padhy, Bikash Ranjan Meher, Anand Srinivasan
Affiliations
Meta-Analysis

Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis

Krishna Nikhila Bonga et al. Obstet Gynecol. .

Abstract

Objective: To evaluate the efficacy and adverse events of fezolinetant for treating vasomotor symptoms (VMS) of menopause.

Data sources: PubMed/MEDLINE, ClinicalTrials.gov , EMBASE, Cochrane Database, Scopus, and WHO International Clinical Trials Registry Platform were searched through June 2023 for publications and randomized controlled trials on fezolinetant compared with placebo in menopausal women who experienced moderate-to-severe VMS.

Methods of study selection: Our literature search identified 330 articles, of which five studies with six reports were included in our meta-analysis per our eligibility criteria.

Tabulation, integration, and results: The risk of bias was evaluated using Cochrane's RoB 2 (Risk of Bias version 2) tool, quality of evidence was graded using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, and outcome measures data for effect size were pooled in random-effects model and rated. A total of 2,168 participants from five randomized clinical trials (six reports) were included. Fezolinetant significantly lowered VMS frequency, with pooled mean difference of 2.62 (95% CI, 1.84-3.41). The pooled mean difference for fezolinetant compared with placebo for the MENQOL (Menopause-Specific Quality of Life) measure was -0.60 (95% CI, -0.92 to -0.28), and the mean percentage improvement in VMS frequency was 22.51% (95% CI, 15.35-29.67). Fezolinetant was associated with improvement in sleep quality when compared with placebo.

Conclusion: Fezolinetant is effective in lowering moderate-to-severe VMS frequency and sleep disturbances in postmenopausal women.

Systematic review registration: PROSPERO, CRD42023427616.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure The authors did not report any potential conflicts of interest.

Similar articles

See all similar articles

References

    1. Paciuc J. Hormone therapy in menopause. Adv Exp Med Biol 2020;1242:89–120. doi: 10.1007/978-3-030-38474-6_6 - DOI
    1. Makara-Studzinska MT, Krys-Noszczyk KM, Jakiel G. Epidemiology of the symptoms of menopause - an intercontinental review. Prz Menopauzalny 2014;13:203–11. doi: 10.5114/pm.2014.43827 - DOI
    1. Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health 2006;96:1226–35. doi: 10.2105/AJPH.2005.066936 - DOI
    1. Woods NF, Mitchell ESJTA. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 2005;118(suppl 12B):14–24. doi: 10.1016/j.amjmed.2005.09.031 - DOI
    1. Freeman EW, Sammel MD, Sanders RJJM. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause 2014;21:924–32. doi: 10.1097/GME.0000000000000196 - DOI

Publication types